YuanDa Medicine (00512) successfully achieved the main clinical endpoints in the Phase III clinical study of TLX591-CDx, an innovative investigational radiopharmaceutical for diagnosing prostate cancer in China.

Zh tng cijng APP xn, Yund yyo (00512) gngb, jtun yng y zhndun qinli i de chungxn zi yn fngshxng hz lin yow (RDC) TLX591-CDx (Illuccix, jn yu Cu 68 PSMA-11) zi Zhnggu jnxng de III q lnchun shyn, jnr qdle jj de dngxin jigu, bng chnggng ddole zhyo lnchun zhngdin. Cwi, jtun yng y zhl qinli i de RDC chnpn TLX591 y zi Zhnggu hup jir guj du zhngxn III q lnchun ynji, wili, ling kun chnpn zh xsh dif, yuwng wi Zhnggu qinli i bngzh di lile gng wi jngqu, goxio de zhndio fng'n.